IMBRUVICA 140 mg film-coated tablets

DRUG3 trials

Sponsors

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting, AbbVie Deutschland GmbH & Co. KG, Ascentage Pharma Group Inc.

Conditions

Chronic Graft Versus Host Disease (cGVHD)Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1

Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

CompletedCTIS2023-507330-24-00

AbbVie Deutschland GmbH & Co. KGChronic Graft Versus Host Disease (cGVHD)

Start: 2019-02-07End: 2025-01-20Target: 14Updated: 2024-12-17

Phase 2

HOVON 158 CLL: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial)

Not yet recruitingCTIS2022-502808-72-00

Hemato-Oncologie voor Volwassenen Nederland (Hovon) StichtingChronic Lymphocytic Leukemia

Target: 85Updated: 2024-12-03

Phase 3

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)

RecruitingCTIS2023-508005-24-00

Ascentage Pharma Group Inc.Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start: 2024-08-01Target: 232Updated: 2025-12-03